L‐asparaginase treatment in acute lymphoblastic leukemia
Top Cited Papers
Open Access
- 7 September 2010
- Vol. 117 (2), 238-249
- https://doi.org/10.1002/cncr.25489
Abstract
Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols. Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL. Three asparaginase preparations are available: the native asparaginase derived from Escherichia coli (E. coli asparaginase), a pegylated form of this enzyme (PEG‐asparaginase), and a product isolated from Erwinia chrysanthemi, ie, Erwinia asparaginase. Clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase, lead to inactivation of E. coli asparaginase in up to 60% of cases. Current treatment protocols include E. coli asparaginase or PEG‐asparaginase for first‐line treatment of ALL. Typically, patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible. Erwinia asparaginase is used as a second‐ or third‐line treatment in European and US protocols. Despite the universal inclusion of asparaginase in such treatment protocols, debate on the optimal formulation and dosage of these agents continues. This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 76 references indexed in Scilit:
- Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2009
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationThe New England Journal of Medicine, 2009
- Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2009
- The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparationsClinical and Experimental Medicine, 2009
- Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95Blood, 2008
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Asparagine Concentration in Plasma After 2 500 IU/m² PEG-Asparaginase i.v. in Children With Acute Lymphoblastic LeukemiaKlinische Padiatrie, 2005
- Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli‐asparaginase or Erwinia‐asparaginase in childhood acute lymphoblastic leukemia (ALL)Pediatric Blood & Cancer, 2005
- Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparationsEuropean Journal of Cancer, 1996
- Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 1986